BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2939203)

  • 1. Phase I study of intravenous menogaril administered intermittently.
    Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
    J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of menogaril in patients with advanced cancer.
    Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
    J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
    Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
    Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
    Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
    Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of intravenous menogaril in patients with advanced breast cancer.
    Sessa C; Gundersen S; ten Bokkel Huinink W; Renard J; Cavalli F
    J Natl Cancer Inst; 1988 Sep; 80(13):1066-9. PubMed ID: 2970554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of oral menogaril administered on three consecutive days.
    Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Joggi J; Kenis Y
    Acta Oncol; 1988; 27(5):517-20. PubMed ID: 2974291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of weekly intravenous administration of menogaril to adults with solid tumors.
    Stewart DJ; Maroun JA; Verma S; Perrault D; Earhart RH
    Am J Clin Oncol; 1989 Dec; 12(6):511-8. PubMed ID: 2531540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
    Long HJ; Powis G; Schutt AJ; Moertel CG
    Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of menogaril in advanced colorectal cancer.
    Holdener EE; ten Bokkel Huinink WW; Decoster G; Ludwig C; Renard G; Pinedo HM
    Invest New Drugs; 1988 Sep; 6(3):227-30. PubMed ID: 2973448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of oral menogaril administered on a once weekly schedule.
    Stewart DJ; Verma S; Maroun JA; Robillard L; Earhart RH
    Invest New Drugs; 1990 Feb; 8(1):43-52. PubMed ID: 2140564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
    Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
    Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of oral menogaril administered daily for 14 consecutive days.
    Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
    Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.
    Buckner JC; Edmonson JH; Ingle JN; Schaid DJ
    Am J Clin Oncol; 1989 Oct; 12(5):384-6. PubMed ID: 2529759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
    Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
    Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
    Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL
    Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
    Weiss GR; Brown TD; Kuhn JG; Von Hoff DD; Earhart RH; Adams WJ; Brewer JE; Hosley JD; Kasunic DA
    Invest New Drugs; 1993 Feb; 11(1):17-27. PubMed ID: 8349432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer.
    Kennedy MJ; Donehower RC; Grochow LB; Ettinger DS; Fetting JH; Abeloff MD
    Invest New Drugs; 1990 Aug; 8(3):289-94. PubMed ID: 2148742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University.
    Cruz JM; Case LD; Dalton HB; Ramseur WL; Richards F; Jackson DV; Muss HB; Zekan PJ; Brodkin RA; Brown RC
    Invest New Drugs; 1992 Apr; 10(1):35-7. PubMed ID: 1535064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.
    Leyvraz S; Ohnuma T; Lassus M; Holland JF
    J Clin Oncol; 1985 Oct; 3(10):1385-92. PubMed ID: 3900302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
    Stewart DJ; Eisenhauer EA; Skillings J; Pritchard KI; Buckman R; VAndenberg T; Verma S; Aitken S; Norris B
    Ann Oncol; 1992 Mar; 3(3):201-4. PubMed ID: 1534021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.